Search clinical trials for: Low dose of IL-2

Total 438418 results

Peking University People's Hospital

Unknown

The Incidence of Infection in Treatment of Low-dose IL-2 of SLE Patients

Infection

China
MetaPhore Pharmaceuticals

Suspended

Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2

IL-2 Induced Hypotension

United States
Peking University Third Hospital

Recruiting

Low Dose IL-2 in the Treatment of Immune-associated ALS Syndrome

Amyotrophic Lateral Sclerosis

China
Sheba Medical Center

Recruiting

Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients

Malignant Melanoma Stage IV

Israel
Oslo University Hospital

Completed

Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma

Malignant Melanoma
Selecxine

Recruiting

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination

Advanced Solid Tumor

United States, Australia, Korea, Republic of
Peking University People's Hospital
Monash University

Completed

Low-dose IL-2( Interleukin-2) Treatment in SLE

Systemic Lupus Erythematosus

China
Liu Tian

Recruiting

Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

China
Bioniz Therapeutics

Completed

A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL

LGL Leukemia | CTCL

United States
William Grosh, MD

Withdrawn

Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer (UVA-AM-002)

Melanoma | Carcinoma, Renal Cell

United States
Assistance Publique - Hôpitaux de Paris
Iltoo Pharma

Completed

Low-dose IL-2 to the Kinetics of Regulatory T-cell in Healthy Volunteers (HEALTHIL-2)

Healthy Volunteers

France
Bioniz Therapeutics
Celerion

Completed

A Multiple-Dose Study of Intravenous BNZ132-1-40 in Healthy Adult Subjects

Safety and Tolerability in Healthy Subjects

United States
National Institute of Allergy and Infectious Diseases...

Completed

Umbrella Study for HIV Infected Adults Enrolled in NIAID-Funded Interleukin-2 Studies

HIV Infections

United States
Brigham and Women's Hospital

Terminated

Novel Strategies to Improve Immunomodulation and Non-invasive Clinical Monitoring in VCA

Abdominal Wall Defect | Amputation, Traumatic | Amputation;Traumatic;Old | Face Injury | Face; Deformity

United States
Peking University People's Hospital

Completed

Anti-infection of Low-does IL-2 in SLE

Systemic Lupus Erythematosus

China
Iovance Biotherapeutics, Inc.

Active, not recruiting

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
University of Minnesota

Completed

Adoptive Transfer of Haploidentical Natural Killer Cells and IL-2

HIV

United States
jiangjingting

Unknown

Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma

Lymphoma, B Cell

China
University of Chicago

Terminated

Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence

Melanoma | Neoplasm Metastasis

United States
Peking University People's Hospital

Completed

Low-dose Recombinant Human IL-2 for the Treatment of Relapsing Polychondritis

Relapsing Polychondritis

China
China Medical University Hospital

Completed

Functional Plasticity of Human IL-17-producing CD8+ T Cells

IL-17+ CD8 T Cells in Cancer Patients

Taiwan
Anil K. Chandraker, MD

Terminated

Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation

Kidney Transplantation

United States
Iltoo Pharma

Completed

ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE) (LUPIL-2)

Systemic Lupus Erythematosus

France, Spain, Mexico, Austria, Germany, Bulgaria, Italy, Mauritius, Portugal, Romania
Cambridge University Hospitals NHS Foundation Trust

Not yet recruiting

The Effect of Low-dose Interleukin-2 on the Immune Landscape of Human Atherosclerotic Plaques at Single Cell Resolution. (ELLIPSE)

Carotid Artery Plaque | Carotid Atherosclerosis | TIA

United Kingdom
Assistance Publique - Hôpitaux de Paris
Iltoo Pharma

Completed

Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder (DEPIL-2)

Bipolar Depression

France
Istanbul Medeniyet University

Completed

Roles of T Helper 1 Cytokines in Type 1 Diabetes

Type 1 Diabetes

Turkey
National Cancer Institute (NCI)

Completed

A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas

Non Hodgkin's Lymphoma | Hodgkin's Disease

United States
Peking University People's Hospital
Monash University; Beijing ShuangLu Pharmaceutical Co., Ltd.

Unknown

A Pilot-Study With Low-dose hrIL-2 for the Treatment of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

China
Vical

Completed

A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma

Metastatic Melanoma

United States
Providence Health & Services
Prometheus Laboratories

Active, not recruiting

Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma. (SBRT/IL-2)

Metastatic Melanoma

United States
AgonOx, Inc.
Providence St Joseph Health; Phio Pharmaceuticals Corp.

Recruiting

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors (ACT)

Melanoma | Gynecologic Cancer | Colorectal Cancer | Lung Cancer | HNSCC | Urogenital Cancer

United States
National Institute of Allergy and Infectious Diseases...
Chiron Corporation

Completed

Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People (STALWART)

HIV Infections

United States, Australia, Argentina, Morocco, Portugal, Thailand, Chile, Italy, Poland, Spain, United Kingdom
National Cancer Institute (NCI)

Completed

Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase

Melanoma | Neoplasm Metastasis

United States
National Cancer Institute (NCI)

Completed

A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas

Rhabdomyosarcoma | Ewing's Sarcoma

United States
Centre Hospitalier St Anne
For Drug Consulting

Recruiting

Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD (IL-2-AD)

Alzheimer Disease

France
Scott B. Snapper, MD PHD

Completed

Low Dose IL-2 for Ulcerative Colitis

Ulcerative Colitis

United States
University Hospital, Limoges

Withdrawn

Treatment of Steroid Dependent Idiopathic Nephrotic Syndrome in Children With Low Doses of Interleukin 2: a Pilot Study (NIL-2 pilote)

Nephrotic Syndrome Steroid-Dependent | Interleukin 2
Biohaven Pharmaceuticals, Inc.
Dana-Farber Cancer Institute

Recruiting

Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients

Multiple Myeloma

United States
National Institute of Allergy and Infectious Diseases...

Completed

Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV

HIV Infections

United States
Providence Health & Services
Prometheus Laboratories; Cytokine Working Group

Active, not recruiting

Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

Renal Cell Carcinoma

United States
Peking University People's Hospital
Monash University; Beijing ShuangLu Pharmaceutical Co., Ltd.

Completed

A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome

Primary Sjögren's Syndrome

China
Efficacy Care R&D Ltd
Hadassah Medical Organization

Unknown

Estimation of Delirium Data Completeness

Delirium | Delirium, Cause Unknown | Delirium of Mixed Origin | Delirium Confusional State | Delirium Drug-Induced

Israel
Motus GI Medical Technologies Ltd

Completed

Clinical Investigational Plan: Evaluation of the Performance of the Motus Cleansing System

CRC

Israel
HeJing

Completed

Low-dose IL-2 Treatment on Behcet's Disease

Behcet's Disease

China
National Institute of Allergy and Infectious Diseases...

Completed

Studies of Influenza Vaccine and Tetanus-Pneumococcal Vaccine in HIV-infected Patients Receiving Interleukin-2

HIV Infections

United States, Denmark
Onur Boyman, MD

Completed

Low-dose Interleukin-2 for Treatment of Systemic Lupus Erythematosus (Charact-IL-2)

Lupus Erythematosus, Systemic

Switzerland
Mt. Sinai Medical Center, Miami
Bayer; Chiron Corporation

Completed

Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma

Malignant Melanoma

United States
Mariano Marcos State University

Completed

Combined Land- and Water-Based Core and Lower Extremity Strength Training in Improving the Jump Performance Among Volleyball and Basketball Players

Athletes

Philippines
Eisai Co., Ltd.

Completed

Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study)

Partial Onset Seizures

Japan, Korea, Republic of

Search clinical trials for: Low dose of IL-2

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations